Event

Cancer immunotherapy and immuno-oncology are rapidly emerging. Since immune checkpoint inhibitors targeting CTLA4 and PD1/PDL1 have been FDA approved for a number of cancers including NSCLC, pulmonary providers face increasing numbers of patients with respiratory complications of these agents. The appropriate recognition, diagnosis and management of these life threatening complications is crucial to patient outcomes. This session will provided attendees with the skills to do this in their daily practice.